



VGX Pharmaceuticals Signs Marketing and License Agreement for Asia and Other Developing Regions

Blue Bell, PA – February 21, 2007 –

VGX Pharmaceuticals announced today that the Company has granted VGX International, its publicly traded (KSE: 011000) Affiliate based in Seoul, Korea, an exclusive right to sell and market the Company's investigational HIV compound PICTOVIR™ for the countries in Asia and other developing regions including Africa. PICTOVIR™ is currently in Phase II clinical trials in multiple sites in the US and has not yet been approved for sale for treating HIV. The present agreement follows on the previously announced commercialization agreement between the two companies for VGX-1027, VGX's lead candidate in development for anti-inflammatory diseases including Type I diabetes.

Currently 30 to 50 percent of patients with HIV infections who are treated with current drug regimens develop resistance to one or more antiretroviral drugs, reducing the treatment options available to them. Since there is no known effective cure or vaccine for AIDS, HIV drug resistance has become a serious treatment concern. There is a great need for a new class of drug compounds to combat drug resistance observed with existing compounds.

The first PICTOVIR™ Phase I/II clinical study was completed in 2005 under an IND held by the National Institutes of Allergy and Infectious Diseases in collaboration with VGX Pharmaceuticals. Based upon the preliminary results, VGX opened its own IND to support additional Phase II clinical trials for PICTOVIR™ with higher doses to determine the dosage level necessary to achieve a clinically significant antiviral effect.

The Company's other clinical development programs include VGX-410C for chronic HCV infection, which is currently in Phase II clinical trials in the US. In addition, several new Phase I clinical trials are being prepared to be initiated with a strong pipeline, which includes VGX-150 for Melanoma and VGX-100 for Lymphoma/Leukemia and Gastric Cancer as well as VGX-1027 for the treatment of Rheumatoid Arthritis and Type 1 Diabetes.

Cautionary Factors That May Affect Future Results - Materials in this Press Release contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of VGX stock. It is also important to read the disclosure notice contained in many of the individual VGX documents available on www.vgxp.com as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.

About VGX Pharmaceuticals

VGX Pharmaceuticals is a biopharmaceutical company with small molecules and biologics product candidates for the treatment of infectious diseases, cancer and inflammatory diseases. The Company's clinical development programs include PICTOVIR™ for HIV infection and VGX-410C for chronic HCV infection, both of which are currently in Phase II clinical trials. In addition, Phase I clinical trials will be initiated in 2007 for VGX-150 for the treatment of Melanoma and VGX-1027 for inflammatory diseases. VGX's research pipelines include new generation of DNA vaccines and therapeutics as well as CELLECTRA™, a proprietary DNA delivery device. The product candidates and technology programs are protected by the Company's extensive global intellectual property portfolio. More information about VGX can be found at www.vgxp.com.

Company Contact:

Kevin W. Rassas
Senior Vice President
Tel. 267.440.4208
Fax 267.440.4242
E-mail: Rassas@vgxp.com
www.vgxp.com